Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]

2270 reported adverse events

Drugs of this class: DAPRODUSTAT VADADUSTAT

These side effects are most commonly reported by patients taking drugs of the Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC] class:

# Side effect Count
0 HOSPITALISATION 301
1 OFF LABEL USE 182
2 PRODUCT USE ISSUE 163
3 DEATH 135
4 HAEMOGLOBIN DECREASED 119
5 CARDIAC FAILURE 105
6 RENAL IMPAIRMENT 102
7 HAEMOGLOBIN INCREASED 91
8 DYSPHAGIA 83
9 MARASMUS 77
See all common reactions for Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]

Drugs of the Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 CYLINDRURIA 2 0.2000
1 CAMPYLOBACTER SEPSIS 3 0.0938
2 CEREBRAL MICROINFARCTION 3 0.0517
3 MARASMUS 77 0.0506
4 ANDROGENS ABNORMAL 2 0.0455
5 SHUNT OCCLUSION 18 0.0354
6 MEDICAL DEVICE SITE THROMBOSIS 3 0.0291
7 SHUNT STENOSIS 7 0.0253
8 GASTRIC FISTULA 11 0.0246
9 THERAPEUTIC DRUG MONITORING ANALYSIS NOT PERFORMED 6 0.0203
See all enriched reactions for Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]